Research and development

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Innodata, Fox Factory, Lantronix, and Palo Alto Networks and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 30, 2024
Research, Class Action, Growth, Palo Alto Networks, Intelligence, Federation, EPS, Internet of things, PANW, Defendant, Internet, News, Transport, AI, Nature, Complaint, Silicon, City, P.C, Goldengate, Research and development, Fox Factory, Wolfpack, Marketing, IOT

Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.

Key Points: 
  • Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.
  • On this news, the price of Innodata common stock declined by $3.74 per share, or approximately 30.5%, on February 15, 2024.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Retrieved on: 
Friday, March 29, 2024
MSD, Biochemistry, Daiichi Sankyo, Patient, Knowledge, CMC, Cancer, University, Head, Spacecraft, Senior, Research and development, Drug development, Molecular biology, ANL, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.
  • Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC at CStone Pharmaceuticals, at which he provided strategic leadership and oversight to the research, early clinical development, and CMC aspects of the entire CStone’s pipeline.
  • “We are very pleased to have Dr. Tse join our senior leadership team,” said Carsten Lu, CEO and Chairman of Adlai Nortye.
  • “I'm keen to leveraging my experiences with the outstanding team at Adlai Nortye and unlock the full potential of our pipeline.”

Innodata Shareholder Lawsuit Filed By Block & Leviton – Investors Who Have Lost Money Should Contact The Firm

Retrieved on: 
Thursday, March 28, 2024
Research, Certification, Block & Leviton, Growth, District court, United States district court, Defendant, News, AI, Nature, Silicon, Complaint, Goldengate, Research and development, Wolfpack, Marketing

and is brought on behalf of investors that incurred damages on their purchases in Innodata, Inc. securities between May 9, 2019 and February 14, 2024, inclusive.

Key Points: 
  • and is brought on behalf of investors that incurred damages on their purchases in Innodata, Inc. securities between May 9, 2019 and February 14, 2024, inclusive.
  • A class has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.
  • You can learn more about us at our website, www.blockleviton.com , or call (617) 398-5600 or email [email protected] with any questions.

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, TFF, Administration, Conference, Patient, IPA, EAP, Mortality, G&A, Lung transplantation, Insurance, AAAM, Microsoft Access, Research and development, Infection, Safety, FDA, Heart, Corporation, Pharmaceutical industry

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023.
  • For TFF TAC, the Company presented data showing that eight out of eight patients successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • In the fourth quarter 2023, the Company announced the appointment of three new members of its Board of Directors, including Thomas B.

QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss

Retrieved on: 
Thursday, March 28, 2024
Research, Financial management, Growth, Partnership, ISP, Patient, PALM, Mental health, GAD-7, Research and development, EHR, Marketing, Health, Nursing

Moreover, the Company significantly reduced its net operating loss, underscoring its enhanced operational efficiency and fiscal stewardship.

Key Points: 
  • Moreover, the Company significantly reduced its net operating loss, underscoring its enhanced operational efficiency and fiscal stewardship.
  • Revenue Growth: QHSLab achieved revenues of $1,408,995 in 2023, a notable increase from $1,243,186 in 2022.
  • Gross Profit and Margin Improvement: The company generated a gross profit of $793,607 with a gross margin increase to 56.3% in 2023 from 49.8% in 2022.
  • Reduced Net Operating Loss: QHSLab markedly reduced its net operating loss to $(240,158) in 2023 from $(560,539) in 2022, highlighting the Company’s overall improvement in operating efficiency and financial management.

Vast Renewables Limited Announces Operational and Financial Results for First Half of Fiscal 2024

Retrieved on: 
Thursday, March 28, 2024
Hydrogen, Smith International, FEED, Bank of Montreal, Electricity, Financial management, General Electric, Solar, VS1, SM1, Électricité de France, CFO, Partnership, CSIRO, Oil Search, ARENA, California Resources Corporation, Aviation, Carbon, Eye, Investment, Convertible, Research and development, Occidental Petroleum, BMO Capital Markets, CSP, Business, Calendar, Government, Engineering, Renewable energy

SYDNEY, Australia, March 28, 2024 (GLOBE NEWSWIRE) -- Vast Renewables Limited (“Vast” or the “Company”) (Nasdaq: VSTE), a renewable energy company specializing in concentrated solar thermal power (“CSP”) energy systems that generate zero-carbon, utility-scale electricity and industrial process heat today announced operational and financial results for the first half of the Company’s fiscal 2024, comprising the six months ended December 31, 2023.

Key Points: 
  • During the first half of fiscal year 2024, Vast announced several funding commitments from strategic partners.
  • “The support Vast has received from our strategic partners has been very meaningful to the progress of our company, both from a financial as well as operational standpoint,” said Craig Wood, CEO of Vast.
  • During the first half of fiscal year 2024, Vast continued to make progress on its first utility-scale project for power generation, known as VS1, located in Port Augusta in South Australia.
  • As of December 31, 2023, Vast had total diluted common shares outstanding of 29,291,884.

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Retrieved on: 
Thursday, March 28, 2024
Patient, Conference, Research and development, Hudson Yards, Cancer, PCSA, Safety

HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference.

Key Points: 
  • HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference.
  • David Young, Processa’s President of Research & Development, will participate virtually.
  • The conference is being held on April 3 – 4, 2024 at Cooley Law, 55 Hudson Yards, New York, NY 10001.

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Hook effect, Administration, U.S. FDA, Pre-exposure prophylaxis, Risk, COVID-19, Ageing, SARS-CoV-2, Research and development, Clinical trial, Vaccination, Immunodeficiency, Food, FDA, Vaccine

“We made remarkable progress throughout 2023 and in recent months.

Key Points: 
  • “We made remarkable progress throughout 2023 and in recent months.
  • Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
  • Cash Position: Cash and cash equivalents were $200.6 million as of December 31, 2023.
  • Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023, compared to $2.23 for the year ended December 31, 2022.